Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

201
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

115
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

Atorvastatin for Prevention of Amikacin-induced Electrolytes Imbalances; a Randomized Clinical Trial

Pages

  627-634

Abstract

 Aminoglycosides are still widely used for treatment of gram-negative sepsis in critically ill patients. The most reported electrolyte abnormalities related to these drugs are hypokalemia, hypomagnesemia, and hypocalcemia. In this study potential benefit of Atorvastatin in Prevention of Amikacin-induced Electrolytes imbalances has been evaluated. In this trial 44 patients were assigned to the Atorvastatin or placebo group based on the simple randomization method. Atorvastatin group received Amikacinwith dose of 15 mg/kg/day in two equal divided doses every 12 h as intravenous infusion during 30 min and Atorvastatin 40 mg tablet as daily oral dose for 7 days. Patients in the placebo group received same dose of Amikacinand placebo tablet (Placebo group) for at least 7 days. Serum electrolytes (sodium, potassium, calcium, phosphor and magnesium) concentrations, blood urea nitrogen and serum creatinine levels were measured at day 0 and end of the study. Baseline mean ± SDof serum potassium concentration in the Atorvastatin and placebo group was 4. 07± 0. 37 and 4. 15 ± 0. 53 meq/l respectively (p=0. 88). Serum potassium concentration remained unchanged at the end of the study in the Atorvastatin group (P=0. 61) but significantly decreased from 4. 15 ± 0. 53 to 3. 80 ± 0. 55meq/l in the placebo group at day 7(P = 0. 02). In this pilot study, Atorvastatin as 40 mg daily oral dose prevented renal potassium loss during course of Amikacin therapy in the critically ill patients. In the future well designed randomized clinical trials with adequate sample size, renoprotective effects of statins should be examined.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    HEYDARI, BEHROOZ, KHALILI, HOSEIN, DASHTI KHAVIDAKI, SIMIN, BEIGMOHAMMADI, MOHAMMAD TAGHI, & MOHAMMADI, MOSTAFA. (2016). Atorvastatin for Prevention of Amikacin-induced Electrolytes Imbalances; a Randomized Clinical Trial. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), 15(2), 627-634. SID. https://sid.ir/paper/288615/en

    Vancouver: Copy

    HEYDARI BEHROOZ, KHALILI HOSEIN, DASHTI KHAVIDAKI SIMIN, BEIGMOHAMMADI MOHAMMAD TAGHI, MOHAMMADI MOSTAFA. Atorvastatin for Prevention of Amikacin-induced Electrolytes Imbalances; a Randomized Clinical Trial. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR)[Internet]. 2016;15(2):627-634. Available from: https://sid.ir/paper/288615/en

    IEEE: Copy

    BEHROOZ HEYDARI, HOSEIN KHALILI, SIMIN DASHTI KHAVIDAKI, MOHAMMAD TAGHI BEIGMOHAMMADI, and MOSTAFA MOHAMMADI, “Atorvastatin for Prevention of Amikacin-induced Electrolytes Imbalances; a Randomized Clinical Trial,” IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), vol. 15, no. 2, pp. 627–634, 2016, [Online]. Available: https://sid.ir/paper/288615/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top